Marinus Pharmaceuticals Inc (MRNS)

[UFO]

Marinus Pharma Up; Says Data Shows Ganaxolone Reduces Seizures
By Will Daley
(Bloomberg) -- Marinus Pharmaceuticals climbs 30% on vol. 585,000 in pre-market trading after announcing that top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.
Oral ganaxolone showed a "sizable and durable seizure-frequency reduction" in the majority of patients
Some patients achieved an increase in the number of seizure-free days and reported behavioral benefits
NOTE: CDKL5 disorder is a severe, rare genetic epilepsy; earlier this year, MRNS received orphan drug designation from the FDA to develop ganaxolone for the treatment of CDKL5 disorder
Call 9am, 844-277-9448 pw 79335646
Link to statement